Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Robert C. Verdonk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5591-0499; OpenAlex author ID A5015571986. Sources: ClinicalTrials.gov.

Their work

Papers
22
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: none · 2024: 6 papers, 1 trial · 2025: 4 papers · 2026: 6 papers

Papers 22

  1. Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Population. Co-author DOI 10.1002/jso.70391↗
  2. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  3. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  4. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  5. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  6. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01357-y↗
  9. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  10. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  11. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  12. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  13. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  14. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  15. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  16. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  17. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  18. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  19. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  20. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  21. Pancreatitis and pancreatic cancer: A case of the chicken or the egg. Co-author DOI 10.3748/wjg.v27.i23.3148↗
  22. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗

Trials 1

  1. The Role of the Human Microbiome in Patients After Pancreatic Resection. Principal investigator NCT06381882↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lois A. Daamen · 18 shared papers, 2022–2026 · strength 3.10
  2. Izaak Quintus Molenaar · 18 shared papers, 2022–2026 · strength 3.10
  3. Hjalmar C. van Santvoort · 18 shared papers, 2022–2026 · strength 3.10
  4. Marc G. Besselink · 16 shared papers, 2022–2026 · strength 2.53
  5. Vincent Erwin de Meijer · 15 shared papers, 2022–2026 · strength 2.36
  6. Martijn W.J. Stommel · 15 shared papers, 2022–2026 · strength 2.36
  7. Ignace H. J. T. de Hingh · 14 shared papers, 2022–2026 · strength 2.15
  8. Bas Groot Koerkamp · 13 shared papers, 2022–2026 · strength 2.02
  9. Bert A. Bonsing · 12 shared papers, 2022–2026 · strength 1.95
  10. Iris W.J.M. van Goor · 10 shared papers, 2024–2026 · strength 1.73
  11. Vincent P. Groot · 11 shared papers, 2022–2026 · strength 1.71
  12. Sebastiaan Festen · 11 shared papers, 2022–2026 · strength 1.65
  13. Geert Kazemier M · 11 shared papers, 2022–2026 · strength 1.65
  14. Vincent B. Nieuwenhuijs · 10 shared papers, 2022–2026 · strength 1.50
  15. Gert J. Meijer · 9 shared papers, 2022–2026 · strength 1.49
  16. Paul C. M. Andel · 8 shared papers, 2024–2026 · strength 1.43
  17. Thijs J. Schouten · 7 shared papers, 2022–2026 · strength 1.12
  18. Johanna W. Wilmink · 6 shared papers, 2024–2026 · strength 1.07
  19. N C Biesma · 4 shared papers, 2025–2026 · strength 0.93
  20. Nadia Haj Mohammad · 5 shared papers, 2022–2026 · strength 0.83
  21. Lodewijk A.A. Brosens · 6 shared papers, 2022–2024 · strength 0.81
  22. Judith de Vos‐Geelen · 4 shared papers, 2025–2026 · strength 0.77
  23. Hanneke W.M. van Laarhoven · 4 shared papers, 2024–2026 · strength 0.70
  24. Geertjan van Tienhoven · 4 shared papers, 2024–2026 · strength 0.64
  25. Hanne D. Heerkens · 3 shared papers, 2024–2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.